APLS_JPM2025_presentation.pdf

《APLS_JPM2025_presentation.pdf》由会员分享，可在线阅读，更多相关《APLS_JPM2025_presentation.pdf（32页珍藏版）》请在三个皮匠报告上搜索。

1、Boldly delivering life-changing medicinesCedric Francois,M.D.,Ph.D.Co-Founder,Chief Executive Officer and PresidentJanuary 13,20252Forward-looking statementsStatements in this presentation about future expectations,plans and prospects,as well as any other statements regarding matters that are not hi

2、storical facts,may constitute“forward-looking statements”within the meaning of The Private Securities Litigation Reform Act of 1995.Such forward-looking statements include the Companys plans,strategies and expectations for its preclinical,clinical and commercial development of its products and produ

3、ct candidates,its expectations regarding the sNDA for pegcetacoplan for the treatment of for C3G and primary IC-MPGN and the potential commercialization thereof,its plans to initiate Phase 3 studies of pegcetacoplan in FSGS and DGF and the Companys expectations regarding achieving profitability and

4、the timing thereof.The words“anticipate,”“believe,”“continue,”“could,”“estimate,”“expect,”“intend,”“may,”“plan,”“potential,”“predict,”“project,”“should,”“target,”“will,”“would”and similar expressions are intended to identify forward-looking statements,although not all forward-looking statements cont

5、ain these identifying words.Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors,including adjustments to the Companys preliminary revenue figures resulting from,among other things,the completion of financial closing an

6、d review procedures for the quarter and year ended December 31,2024;whether the results of the Companys clinical trials for EMPAVELI,SYFOVRE,or any of its future products will warrant regulatory submissions to the FDA or equivalent foreign regulatory agencies;whether pegcetacoplan will receive appro